Micromet to Present at Two Upcoming Investor C...(inical stage antibody is adecatumumab (M...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Micromet to Present at Two Upcoming Investor Conferences
Date:2/7/2008
inical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM expressing solid tumors. Adecatumumab is being developed by Micromet in collaboration with Merck Serono in a phase 1b clinical trial evaluating MT201 in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (TRC093), a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.
'/>"/>
| SOURCE Micromet, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
6. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Genelabs Technologies to Present at the BIO CEO & Investor Conference
10. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Post Your Comments:
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2
[0] Lyric Presents the Sounds of the Season[0] Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery[1] Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Other Biology Technology:NxStage Medical Announces Needle Supply Agreement with DaVita 2Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 2Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 3Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 4Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 5DRI Capital Launches Structured Finance Fund 2
Breaking Biology News(10 mins):New York autopsies show 2009 H1N1 influenza virus damages entire airway 2New York autopsies show 2009 H1N1 influenza virus damages entire airway 3Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2Genome BC collaborates with Chile and Norway to sequence salmon genome 2Sosei Assigns AD 923 Assets to Pharmasol 5243 1Sosei Assigns AD 923 Assets to Pharmasol 5243 2Continuing racial differences in HIV prevalence in US 58907 1Continuing racial differences in HIV prevalence in US 58907 2Continuing racial differences in HIV prevalence in US 58907 3Health Education Solutions 26apos 3B Advanced Cardiac Life Support Course Gains Approval from American Academy of Family Physicians 58905 1Health Education Solutions 26apos 3B Advanced Cardiac Life Support Course Gains Approval from American Academy of Family Physicians 58905 2
Other Biology News:Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 2Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 3Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 4Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |